JP Morgan Chase’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$271M Buy
1,804,676
+1,212,024
+205% +$186M 0.02% 579
2025
Q4
$81.7M Buy
592,652
+55,109
+10% +$7.22M 0.01% 1042
2025
Q3
$68.9M Buy
537,543
+82,226
+18% +$10M ﹤0.01% 1203
2025
Q2
$55.1M Sell
455,317
-88,021
-16% -$9.92M ﹤0.01% 1277
2025
Q1
$60.6M Buy
543,338
+120,196
+28% +$12.8M ﹤0.01% 1206
2024
Q4
$41.2M Buy
423,142
+111,066
+36% +$11.8M ﹤0.01% 1448
2024
Q3
$35.9M Sell
312,076
-5,738
-2% -$651K ﹤0.01% 1553
2024
Q2
$33.8M Sell
317,814
-87,017
-21% -$8.73M ﹤0.01% 1473
2024
Q1
$39.2M Buy
404,831
+54,370
+16% +$5.57M ﹤0.01% 1426
2023
Q4
$35.4M Sell
350,461
-9,438
-3% -$911K ﹤0.01% 1425
2023
Q3
$36.7M Sell
359,899
-27,138
-7% -$2.75M ﹤0.01% 1269
2023
Q2
$39.1M Sell
387,037
-24,038
-6% -$2.4M ﹤0.01% 1231
2023
Q1
$37.8M Sell
411,075
-24,656
-6% -$2.15M ﹤0.01% 1235
2022
Q4
$39.5M Sell
435,731
-111,014
-20% -$9.35M 0.01% 1235
2022
Q3
$41.6M Sell
546,745
-116,250
-18% -$9.64M 0.01% 1139
2022
Q2
$56M Buy
662,995
+444,401
+203% +$39M 0.01% 987
2022
Q1
$19.2M Sell
218,594
-49,776
-19% -$4.31M ﹤0.01% 1794
2021
Q4
$23.5M Sell
268,370
-38,165
-12% -$3.17M ﹤0.01% 1691
2021
Q3
$25.1M Buy
306,535
+4,378
+1% +$394K ﹤0.01% 1586
2021
Q2
$27.6M Buy
302,157
+16,007
+6% +$1.43M ﹤0.01% 1577
2021
Q1
$24.5M Sell
286,150
-96,641
-25% -$8.67M ﹤0.01% 1580
2020
Q4
$36.1M Buy
382,791
+24,827
+7% +$2.17M 0.01% 1242
2020
Q3
$31.2M Buy
357,964
+11,551
+3% +$1M 0.01% 1216
2020
Q2
$30.3M Sell
346,413
-83,295
-19% -$7.19M 0.01% 1121
2020
Q1
$35.4M Buy
429,708
+17,098
+4% +$1.53M 0.01% 948
2019
Q4
$39.1M Sell
412,610
-221,899
-35% -$19.9M 0.01% 1101
2019
Q3
$55.1M Buy
634,509
+213,328
+51% +$19.2M 0.01% 900
2019
Q2
$38.3M Sell
421,181
-109,595
-21% -$9.28M 0.01% 1123
2019
Q1
$45.7M Sell
530,776
-584,040
-52% -$46.9M 0.01% 1008
2018
Q4
$85.7M Buy
1,114,816
+489,263
+78% +$38.1M 0.02% 677
2018
Q3
$48.3M Sell
625,553
-157,012
-20% -$11.6M 0.01% 1036
2018
Q2
$53M Buy
782,565
+5,224
+0.7% +$360K 0.01% 939
2018
Q1
$56.3M Buy
777,341
+43,007
+6% +$3.27M 0.01% 875
2017
Q4
$55.2M Buy
734,334
+16,737
+2% +$1.26M 0.01% 925
2017
Q3
$54.5M Buy
717,597
+34,406
+5% +$2.6M 0.01% 882
2017
Q2
$51.1M Buy
683,191
+87,384
+15% +$6.19M 0.01% 900
2017
Q1
$39.6M Sell
595,807
-269,413
-31% -$18M 0.01% 1054
2016
Q4
$56.5M Buy
865,220
+346,653
+67% +$22.5M 0.01% 834
2016
Q3
$36.7M Sell
518,567
-996,024
-66% -$72.6M 0.01% 981
2016
Q2
$112M Sell
1,514,591
-143,846
-9% -$9.94M 0.03% 529
2016
Q1
$108M Buy
1,658,437
+143,110
+9% +$9.74M 0.03% 526
2015
Q4
$117M Sell
1,515,327
-300,811
-17% -$23.9M 0.03% 515
2015
Q3
$150M Sell
1,816,138
-9,601
-0.5% -$854K 0.04% 435
2015
Q2
$161M Sell
1,825,739
-24,325
-1% -$2.23M 0.04% 454
2015
Q1
$163M Sell
1,850,064
-2,030
-0.1% -$180K 0.04% 482
2014
Q4
$154M Sell
1,852,094
-353,384
-16% -$29.3M 0.04% 500
2014
Q3
$186M Buy
2,205,478
+105,074
+5% +$8.5M 0.04% 423
2014
Q2
$170M Buy
2,100,404
+19,755
+0.9% +$1.55M 0.04% 425
2014
Q1
$159M Buy
2,080,649
+197,729
+11% +$14.4M 0.04% 424
2013
Q4
$136M Sell
1,882,920
-379,134
-17% -$26.4M 0.04% 443
2013
Q3
$155M Buy
2,262,054
+680,923
+43% +$45.1M 0.05% 401
2013
Q2
$100M Buy
+1,581,131
New +$103M 0.03% 507

Other funds holding NVS

JP Morgan Chase's NVS Position: Q1 2026 in Review

JP Morgan Chase increased its Novartis (NVS) stake by 205% in Q1 2026, buying an estimated $186M and bringing the position to 1,804,676 shares worth $271M. The position accounts for 0.02% of the portfolio, ranked #579.

JP Morgan Chase first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • JP Morgan Chase held 1,804,676 shares of Novartis worth $271M as of Q1 2026.
  • JP Morgan Chase bought 1,212,024 Novartis shares in Q1 2026, an estimated $186M.
  • Novartis made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #579 holding.
  • JP Morgan Chase first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.